Shanghai Send Medical Completes Nearly RMB 200 Million Series D Financing, Ushering in a New Era of Precision Non-Invasive Healthcare

VCBeat has learned that Green Medical Era, a pioneer in the non-invasive era—Shanghai Shende Green Medical Era Co., Ltd. (hereinafter referred to as “Green Medical Era”)—has recently announced the completion of its Series D financing round, raising nearly RMB 200 million. Over the past three years, Green Medical Era has demonstrated strong growth momentum, securing four consecutive rounds of financing with a cumulative total of nearly RMB 400 million. The previous Series C financing took place in October 2021, and the company’s valuation has doubled within the last two years, officially entering a rapid development phase for product commercialization and capital market listing. This round of financing was jointly invested by Zhuji Huiri Yingtian Equity Investment Partnership (Limited Partnership), Hefei Industrial Investment Promotion Phase II Venture Capital Fund Partnership (Limited Partnership), Tianjin Shenxin Jincheng Enterprise Management Partnership (Limited Partnership), and Ningbo Jinming Chuangjia Investment Partnership (Limited Partnership). The funds from this round will be used for the research and development, clinical trials, regulatory approval, market promotion, IPO counseling, and global industrial layout of new products in the Magnetic Wave Knife series. Key initiatives include advancing the NeuroKnife, ProstateKnife, and ultrasound-based medical aesthetics products, accelerating the construction of facilities in Hefei and Beidaihe, and establishing and operating subsidiaries in Europe and the United States.

The Report to the 20th National Congress of the Communist Party of China explicitly stated that China will accelerate the development of a Healthy China, prioritizing the protection of people’s health as a strategic priority. It emphasized the core role of “innovation” in the overall framework of China’s modernization, ushering in a golden period of development for technology-driven medical device companies.

Multiple magnetic wave knife products available overseas have obtained regulatory approvals from authorities in the European Union, the United States, Canada, Japan, South Korea, China, Singapore, and other countries and regions, and are being clinically applied in over one hundred leading medical centers. Meanwhile, China’s large population base and advancing aging trend have made it the most critical market in the global strategic landscape.

Green Medical Era closely aligns with national strategies, leveraging nearly four decades of major scientific and technological achievements from the team of Academician Chen Yazhu at Shanghai Jiao Tong University, a recipient of the Shanghai Science and Technology Merit Award. Through independent innovation, it has overcome critical technological bottlenecks, broken import monopolies, and filled industry gaps by developing the Magnetic Wave Knife—a domestically produced, high-end medical device with high technical content and significant application value. This innovation provides novel medical solutions for the treatment of major diseases such as tumors and neurological disorders, pioneering and leading a new era of non-invasive medicine that follows the ages of open surgery, large-incision surgery, and minimally invasive surgery.

Since its establishment, Green Medical Era has successively received the First Prize of Shanghai Science and Technology Progress Award, been included in the Ministry of Science and Technology’s “13th Five-Year” Key R&D Program for Digital Diagnosis and Treatment Equipment, and undertaken major national and provincial/ministerial-level projects such as the Major Instrument Project of the National Natural Science Foundation. It was also doubly recognized in 2022 as a Shanghai “Innovative SME” and “Specialized, Refined, Differential, and Innovative SME.” In 2023, it jointly undertook the “Key Special Project on Diagnostic and Therapeutic Equipment and Biomedical Materials” under the National Key R&D Program of the 14th Five-Year Plan, in collaboration with Beijing Xuanwu Hospital, Shanghai Jiao Tong University, and United Imaging Healthcare.

Green Medical Era was listed on the “Pioneering Technology List” of Science and Technology Innovation China in 2021, won the Global Grand Prize in the Digital Healthcare Track of the 4th Global Internet Competition in the “AI + Medical Devices” sector in 2022, and was ranked among the Top 50 Most Influential Healthcare Enterprises of 2022 at the 2023 CHC CITIC Securities Healthcare Conference.

Green Medical Era has fully leveraged favorable policies at the national, provincial, and municipal levels—spanning R&D, regulatory approval, and market access—to cultivate a conducive environment for industry development, while actively establishing industrial bases in key central cities across China. Building on its consistent clinical performance domestically and supported by capital investment, the company is proactively implementing its global expansion strategy, integrating comprehensively into the global innovation network to benefit patients worldwide.

Academicians, professors, and students from Jiaotong University have embarked on entrepreneurial ventures, closely integrating medicine and engineering in the research and development of high-end medical devices. They have achieved cross-disciplinary fusion of multi-mode phased-array focused ultrasound technology, magnetic resonance medical imaging with non-invasive thermometry, treatment planning, precise positioning and navigation, real-time efficacy assessment, electromagnetic compatibility, core probe components, electrical drive components, mechanical systems, water cooling, materials, sealing, as well as software, algorithms, medicine, and molecular biology. Building on this foundation and incorporating digital healthcare and intelligent AI technologies, they have developed integrated smart diagnostic and therapeutic equipment that combines hardware and software.

Innovation in high-end medical devices requires interdisciplinary talents within the industry who can understand and identify clinical needs, translate them into specific product designs, break them down into parameter requirements for each technical component, and organically link needs with products. Built upon the nearly 40 years of arduous and collaborative efforts by approximately 200 master’s and doctoral researchers at the Institute of Medical Instruments, School of Biomedical Engineering, Shanghai Jiao Tong University, Green Medical Era was founded by nearly 20 full-time master’s and doctoral graduates from Shanghai Jiao Tong University specializing in the interdisciplinary field of medicine and engineering. After ten years of refinement, the team has jointly established an innovative platform for magnetic wave ablation systems, laying a solid foundation for the technological breakthroughs and scalable innovation of this technology.

Group Photo of the Green Medical Era Team

Green Medical Era has established the “1+N+X” innovation development strategy, promoting innovation management at the platform, product line, and product levels across the company. It has built one shared technology platform for Magnetic Wave Knife innovation, achieving comprehensive breakthroughs in software technologies (including intelligent planning, automated control, 3D modeling, and deep learning), hardware electrical technologies (including phased array, tunnel technology, MRI compatibility, and quasi-real-time star topology), and hardware mechanical technologies (including transmission precision, mechanism posture, sealing applications, heat transfer systems, non-magnetic materials, and fatigue strength). This has established robust technical barriers, formed a comprehensive intellectual property protection system, and demonstrated sustained innovation capabilities in the field of “Magnetic Wave Knife.” The company is committed to tackling N therapeutic areas, including the nervous system, body tumors, gynecology, andrology, and orthopedics, while continuously developing X series of products for indications such as Parkinson’s disease, essential tremor, uterine fibroids/adenomyosis, breast tumors, prostate tumors, bone tumors, and ultrasound-based medical aesthetics.

1+N+X Innovation Strategy

N and X represent the direction of innovative value fission, holding infinite possibilities. This innovation strategy carries many important expectations for human health, guiding enterprises to continuously break through higher-end technical fields, develop and produce more advanced medical devices, focus on high-value segmentation for technological breakthroughs, and continuously launch superior treatment solutions with robust performance, extreme cost-effectiveness, better therapeutic effects, fewer side effects, and simpler operations. It also actively explores areas such as "incurable" rare diseases, bringing hope for treatment options and cures to patients.

Green Medical Era's Three Flagship Magnetic Wave Knife Products

Product Structure of the Magnetic Wave Knife

Green Medical Era’s innovative architecture has successfully transitioned from a flat and matrix structure to a business unit model, establishing five major divisions: Innovation, Platform, Software, Head Knife, and Body Knife. The company is currently actively promoting the establishment of a Medical Aesthetics Business Unit. This optimized organizational structure aims to comprehensively address innovation needs, ensure the implementation of innovation strategies, and support future industrial fission. Through strategic resource allocation, resources are reasonably distributed among various business units to support the complex layout of multiple pipelines and the innovative development of diverse products.

Guided by the grand vision of becoming a global leader in non-invasive magnetic wave knife therapeutic devices, Green Medical Era adopts multiple innovative models to break down the barriers between "high-end" and "timeliness." By continuously advancing toward more sophisticated technologies through technological breakthroughs, the company leverages the synergistic power of multiple pumps to balance enterprise production with development.

The Superposition of Follower, Iterative, and Source Innovation Models:

By following the technologies of mature, already-listed imported products, we develop “domestic alternative” products, bypassing the R&D trial-and-error phase to significantly reduce costs and shorten time-to-market. For existing products, we rapidly learn and apply cutting-edge international technologies to achieve leapfrog iterative optimization, incorporating user feedback to implement “micro-innovations” that result in China’s first-of-their-kind products. Meanwhile, we boldly venture into uncharted territory by pioneering new surgical techniques or products, leveraging original technological breakthroughs and disruptive innovation to deliver “industry-first” solutions.

Implement a Horizontal Innovation Strategy: Expand application scenarios and product pipelines horizontally, developing comprehensive product portfolios around specific application scenarios to consolidate competitiveness through the advantage of “more complete” product offerings.

Green Medical Era adheres to a user-centric approach, leveraging its scientific research strengths to establish multi-dimensional short-, medium-, and long-term innovative collaborations with leading tertiary Grade A hospitals and top experts in China. These collaborations span basic research, applied research, and registration clinical trials, forming a closed-loop innovation management system that covers product pre-research, product commercialization, and post-market full lifecycle management. In the short term, the company engages in registration clinical collaborations for follow-on innovative products to accelerate the market launch of domestic alternatives. In the medium term, it focuses on deepening expertise in current therapeutic areas, conducting micro-innovations and animal studies for iterative innovative products, and rapidly advancing human clinical trials. In the long term, it undertakes national and provincial/ministerial-level research projects and product pre-research focused on disruptive innovations, generating scientific outputs such as intellectual property, academic publications, and industrialized products. By establishing deep, long-term partnerships with Key Opinion Leaders (KOLs), Green Medical Era builds a sustainable innovation mechanism, fostering continuous sources of innovation and creating a win-win situation for enterprises, hospitals, and experts.

Green Medical Era has constructed diversified commercial application scenarios. Based on the departmental structures and leading specialties of user hospitals, it has established personalized, multi-department co-built "Magnetic Wave Knife Non-Invasive Diagnosis and Treatment Centers" within the top three Grade A tertiary hospitals across seven major regional centers in China. Furthermore, it is promoting the establishment of non-invasive diagnosis and treatment scenarios integrating "Radiology/Neurosurgery/Gynecology/Orthopedics/Urology departments + Magnetic Wave Knife" at the top ten Grade A tertiary hospitals in 49 cities, including first-tier, new first-tier, and second-tier cities.

Non-Invasive Magnetic Wave Surgery Center

First Wave: The MRI Industry Wave

The explosive growth of the magnetic resonance imaging (MRI) industry has presented unprecedented and significant historical opportunities for the development of the Magnetic Resonance-guided Focused Ultrasound (MRgFUS), or "Magnetic Wave Knife," industry. The MRI sector as a whole is in a period of rapid growth, with market penetration increasing year by year. Since MRI is limited to diagnostic functions—albeit with continually improving diagnostic capabilities—and cannot provide therapeutic interventions, MRI and MRgFUS represent two entirely complementary technological approaches for diagnosis and treatment, respectively. Consequently, numerous domestic and international MRI manufacturers have chosen to form strategic alliances with Green Medical Era to promote bundled product sales, achieve deep technological integration, and share market resources.

Wave 2: The Wave of the Minimally Invasive Industry

The minimally invasive treatment industry is in a period of rapid growth. Driven by stricter regulations and intense competition, the sector is advancing toward standardization and customization, improving cost-effectiveness and service quality, and placing greater emphasis on user experience. Trends such as population aging, favorable policies, domestic substitution, and accelerated capital investment will all propel the rapid rise of the minimally invasive surgery industry. Green Medical Era’s magnetic wave knife technology boasts prominent advantages; as a next-generation therapeutic approach, it is poised for significant expansion.

The Third Wave: The Traditional Ultrasound Therapy Industry

Traditional ultrasound therapy technologies face significant technical challenges, with both surgical safety and efficacy requiring further improvement. Consequently, after a prolonged introduction phase and a brief period of growth, the field has entered a bottleneck stage. The emergence of the next-generation focused ultrasound technology—the Magnetic Resonance-guided Focused Ultrasound (MRgFUS) system, commonly known as "Magnetic Wave Knife"—has posed substantial challenges to the development of traditional ultrasound therapies. As a next-generation focused ultrasound technology, the Magnetic Wave Knife features comprehensive technological upgrades. Its rapid market entry undoubtedly represents a significant strategic opportunity for Green Medical Era.

Wave 4: The Magnetic Wave Knife Industry Surge

Given that magnetic wave knife technology requires the participation of talents from numerous interdisciplinary fields and involves a lengthy R&D process, only a few major competitors are currently engaged in global market competition. Leveraging its robust scientific research support, exceptional cost-effectiveness, high-quality after-sales service, and unique resource endowments, Green Medical Era has the potential to rapidly enter a growth phase and stand out in the market.

Based on an analysis of B-side customer needs, the treatment of tumors and major neurological disorders is trending from invasive to minimally invasive, and further to non-invasive approaches. Hospital physicians are transitioning from traditional surgery to minimally invasive techniques such as radiofrequency and microwave ablation, and subsequently to a range of non-invasive methods. Medical technology and capabilities are inevitably undergoing continuous iteration. Given that conventional ultrasound therapy has failed to fully address clinicians’ needs, and proton and heavy ion therapy (a form of radiation therapy) entails high installation and maintenance costs, Magnetic Resonance-guided Focused Ultrasound (MRgFUS), or “Magnetic Wave Knife,” offers a novel, high-quality solution. It demonstrates significant advantages, particularly in the treatment of certain specific indications.

Based on an analysis of consumer-patient needs, the progression from open surgery to minimally invasive surgery and then to non-invasive surgery inevitably entails an improvement in patient experience. Taking uterine fibroids as an example, patients can undergo treatment via outpatient magnetic resonance-guided focused ultrasound surgery (MRgFUS) without incisions, enabling faster recovery and supporting better eugenic outcomes and reproductive health.

Therefore, dynamically iterating around customer needs to meet the differentiated requirements of physicians and patients, while upholding the core values of “user-oriented, patient-first,” serves as an inexhaustible driving force for the continuous innovation and development of MR-guided focused ultrasound (MRgFUS) systems.

According to a 2022 report in the journal "Informatization Construction," magnetic wave knife (focused ultrasound surgery) currently has over 120 clinical indications, covering gynecological tumors, urological tumors, abdominal tumors, cervical tumors, and neurological disorders of the brain. The market potential and economic benefits are substantial. Taking indications in the three major fields of gynecology, orthopedics, and neurology as examples:

According to literature, approximately 11.21% of women in China suffer from uterine fibroids, with an estimated patient population exceeding 60 million. Current treatment modalities for uterine fibroids include surgical intervention, ablation techniques, and embolization techniques. Among these, surgical intervention accounts for the largest share, reaching 58.46% of the market in 2021. According to the latest research, the sales revenue of China’s uterine fibroid treatment market reached USD 484.6 million in 2021 and is projected to reach USD 949 million by 2028. This implies that once Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS), commonly known as "Magnetic Wave Knife," becomes a primary clinical treatment modality and replaces invasive surgeries, its commercial potential will exceed RMB 3.989 billion.

Metastatic Bone TumorsMetastatic bone tumors, also known as bone metastases, are secondary malignant neoplasms. Statistics indicate that metastatic bone tumors are prevalent among the elderly population, particularly in female patients with breast cancer and male patients with prostate cancer. More than 70% of these patients are prone to developing bone metastases in the late stages of cancer, which is associated with a high mortality rate. It is reported that up to 350,000 patients die from metastatic bone tumors annually in the United States. Currently, treatment modalities for metastatic bone tumors include radiotherapy and analgesics. However, radiotherapy carries the side effect of ionizing radiation, while pharmacological interventions may lead to increased drug resistance and short-lived pain relief. In comparison, Magnetic Resonance-guided Focused Ultrasound (MRgFUS), commonly referred to as "Magnetic Wave Knife," represents a non-invasive therapeutic approach with significant potential for clinical application.

According to the "White Paper on Tremor Patients in China," diseases that cause tremors include essential tremor, Parkinson's disease, neuropathic pain, obsessive-compulsive disorder, and epilepsy. Currently, China has one of the largest populations of tremor patients globally, with over 10 million individuals suffering from essential tremor. The number of Parkinson's disease patients is projected to exceed 4.9 million by 2030. As population aging intensifies, both the size of this patient group and the demand for diagnosis and treatment will continue to grow. Unfortunately, current treatment options for tremor patients are very limited, primarily consisting of medications and surgical interventions such as craniotomy-based radiofrequency ablation, deep brain stimulation (DBS), and Gamma Knife surgery. However, these treatments carry significant clinical risks, involve radiation exposure, and are often difficult for elderly patients to accept due to the invasive nature of craniotomy, resulting in overall high treatment challenges for this patient population. Therefore, as a novel non-invasive, low-risk, and low-radiation treatment modality, Magnetic Resonance-guided Focused Ultrasound (MRgFUS), commonly known as the "Magnetic Wave Knife," offers higher acceptance among elderly patients and lower treatment risks.

According to the assessment report issued by Frost & Sullivan, the potential market size for Green Medical Era’s non-invasive magnetic wave knife is RMB 70 billion. Currently, Green Medical Era has deeply cultivated multiple fields, with several products simultaneously undergoing clinical certification applications, poised to unlock substantial market potential.

Green Medical Era demonstrates a robust momentum driven by technology, commerce, capital, and management. Guided by its grand organizational vision and core values, the company has established fundamental core capabilities in operating the “Magnetic Wave Knife” innovation platform, building intellectual property barriers, facilitating product proliferation, and executing commercial operations. It possesses the ability to construct a comprehensive industry-business synergy system and holds the potential to create an innovative landscape encompassing non-invasive Magnetic Wave Knife technology, products, industry, and ecosystem. As a typical representative of domestically produced high-end innovative medical devices, Green Medical Era is poised to reshape the global healthcare market.

Academician Chen Yazhu, Chief Advisor to Green Medical EraIt was stated that Magnetic Resonance-guided Focused Ultrasound (MRgFUS), commonly known as the "Magnetic Wave Knife," enables non-invasive treatment of gynecological and neurological conditions under MRI guidance. This technology offers numerous unique advantages, including precise targeting, temperature control, efficacy assessment, and intraoperative visualization, boasting broad prospects for development and application. After a decade of dedicated refinement, Professor Shen Guofeng’s team has successfully commercialized the university’s research achievements to benefit patients, achieving remarkable results thus far. Green Medical Era will assume a leading and pioneering role in non-invasive medicine—a position that represents both a challenge and a responsibility. With the highly promising future of non-invasive medical technologies, we look forward to Green Medical Era collaborating with partners across all sectors to jointly strive for the forefront of non-invasive medical technology, achieving significant breakthroughs from inception to commercialization (0 to 1) and from commercialization to large-scale adoption (1 to N) of the Magnetic Wave Knife.

Professor Shen Guofeng, Founder of Green Medical EraGreen Medical Era, as a leading Chinese domestic enterprise in high-end medical devices specializing in magnetic wave knife technology, is dedicated to overcoming technical challenges and commercializing its innovations. The company focuses on the research, development, and production of high-precision, non-invasive therapeutic equipment with fully independent intellectual property rights. It has secured over 100 core intellectual property assets, including patents and software copyrights, and is actively filing patents in multiple countries worldwide to build a robust technological moat. Upholding its original mission, Green Medical Era remains committed to independent innovation and R&D. By collaborating with universities, research institutes, clinical medical institutions, experts, scholars, and partners across the industry chain, the company aims to jointly advance the future health industry and continuously contribute wisdom and strength to the global cause of non-invasive medical healthcare.

Cui Lei, Executive CEO of Green Medical EraIt is stated that a forward-looking innovation strategy is vital to enterprises, playing a key role in driving their medium- and long-term growth. Green Medical Era precisely aligns with national strategies, accurately grasps user needs, and keenly captures the pulse of industrial innovation, striving to realize the ultimate dream of non-invasive care for both doctors and patients. We will consistently adhere to our user-centric approach and original commitment to independent innovation, deepen the integration of medicine and engineering, and thoroughly explore industrial value. Guided by a comprehensive innovation strategy, we will continuously unlock new treatment solutions, balance "speed" and "quality," leverage our first-mover advantage, generate technological dividends, establish a leading market position, benefit patients worldwide, and deliver returns to capital and society.

Wang Xin, Managing Partner of Zhuji Huiri Yingtian Equity Investment Partnership (Limited Partnership), stated: “As the General Partner (GP) of Zhuji Huiri Yingtian, Ningbo Dading Shengye Investment Management Co., Ltd. has consistently focused on identifying original, hard-tech projects. Green Medical Era possesses domestically leading and internationally advanced high-end phased-array ‘Magnetic Wave Knife’ technology for precise, non-invasive diagnosis and treatment. By pioneering the transition from ‘invasive’ to ‘minimally invasive’ and finally to ‘non-invasive,’ it has innovatively ushered in the era of non-invasive medicine.”

We have consistently supported domestic substitution, particularly by empowering outstanding teams that address critical technological bottlenecks. Led by Academician Chen Yazhu (a native of Ningbo) from Shanghai Jiao Tong University and spearheaded by Professor Shen Guofeng, this rare and innovative team has dedicated over three decades to rigorous research. They have mastered core technologies in the field of precise, non-invasive ultrasound diagnosis and therapy guided by advanced imaging modalities such as magnetic resonance imaging (MRI), achieving multiple major scientific breakthroughs with a comprehensive framework of independent intellectual property rights. This technology offers significant advantages, including extremely high positioning accuracy, deep penetration, high focal precision, and high energy delivery. It enables non-invasive treatment without radiation, pain, or anesthesia, with short treatment durations, thereby benefiting both patients and society.

The team has consistently advocated for the strategy of “investing early, investing in small ventures, and investing in technology,” aligning with the standards of the STAR Market. Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS), or “Magnetic Wave Knife,” demonstrates excellent therapeutic efficacy for over one hundred conditions, including uterine fibroids, adenomyosis, bone tumors, and Parkinson’s disease. It addresses a market of trillion-dollar scale encompassing benign and malignant tumors, cardiovascular and cerebrovascular diseases, and neurological disorders. The MRgFUS technology developed by Green Medical Era possesses strong scientific and technological innovation attributes. At this pivotal juncture, where performance is poised to take off and experience explosive growth, we remain firmly bullish on its prospects.

Manager of Hefei Industrial Investment Promotion Phase II Venture Capital Fund Partnership (Limited Partnership): Hefei Industry Investment CapitalIt was stated that Green Medical Era specializes in the business of non-invasive therapeutic devices based on magnetic resonance-guided phased-array focused ultrasound (known as “Magnetic Wave Knife”). The company’s products are pioneering in China and leading globally. In particular, its “Head Knife” product features high technological sophistication, significant value, and scarcity, holding substantial significance for industrialization. Green Medical Era is a scarce, technology-integrated innovative team in the field of focused ultrasound, possessing comprehensive industrialization capabilities such as full-scale technology implementation and product engineering. Hefei Industrial Investment Capital, together with Feidong County of Hefei City, jointly invested in Green Medical Era to introduce the project to Hefei. Innovative medical devices are a key investment focus for Hefei City, and the investment in Green Medical Era represents a landmark case co-created by Hefei Industrial Investment Capital, market-oriented institutions, and county-level authorities. Looking ahead, Hefei Industrial Investment Capital will continue to fulfill its mission as a state-owned investment platform, supporting the high-quality development of the innovative medical device industry in Anhui Province and Hefei City, and striving to build an innovative medical device industrial cluster and innovation system.

Dr. Li Shuang, Chairman and General Manager of Tianjin Shenxin Jincheng Enterprise Management Partnership (Limited Partnership)"The Shen De team has accumulated nearly four decades of experience in the field of medical-engineering integration, developing profound technical expertise and strong capabilities in product commercialization through long-term accumulation. As a domestically produced high-end non-invasive medical device with full independent intellectual property rights, it represents a novel therapeutic approach that benefits the industry, society, and patients. As the Beidaihe New Area Industrial Fund, we are supporting the company’s industrialization process and are confident that it will bring positive surprises to the medical field, ushering in a new era of non-invasive treatment."

Managing Partner of Ningbo Jinming Chuangjia Investment Partnership (Limited Partnership)Statement: Green Medical Era’s strategic layout of its innovative Magnetic Wave Knife product series offers patients a novel, non-invasive, and eco-friendly approach to precision therapy. This initiative promotes the advancement of non-invasive medical care and aligns with the future direction of the healthcare industry. Currently, the company is in a phase of rapid growth, having established in-depth research and clinical collaborations with more than ten renowned Grade A tertiary hospitals across China. Multiple products are currently applying for Innovative Medical Device certifications and Class III Medical Device registration certificates. Its upcoming innovative products for clinical use, including the Neuro Knife and Prostate Knife, have garnered significant attention from relevant clinical departments and the broader healthcare industry. With clear strategic objectives and steady development, the company demonstrates substantial social value and vast market potential. As investors, we are committed to supporting enterprises like Green Medical Era, which possess grand visions, to drive and lead the era of non-invasive medicine.

Dading Investment, as the manager of Zhuji Huiri Yingtian Equity Investment Partnership (Limited Partnership), boasts a core team hailing from top-tier institutions such as Fortune Capital, JD Capital, Hopu Investment, and CITIC. The team members have an average of over 10 years of experience in private equity investment. Their cumulative investment amount in past projects amounts to billions of RMB. The team has operated dozens of outstanding local enterprises, with more than ten companies either already listed or currently under review for listing. Dading Investment emphasizes ecosystem building, with partners including former officials from the China Securities Regulatory Commission (CSRC), the investment banking team of Pacific Securities, and godfather-level industry leaders in China's PE sector.

Dading’s investment sectors include biopharmaceuticals, new energy and new materials, artificial intelligence, big data, semiconductors, and intelligent manufacturing. The company operates dual headquarters in Ningbo and Beijing, and its partners include renowned domestic institutions such as the Chinese Academy of Sciences, the University of Science and Technology of China, and Fortune Capital. Recently, the company was once again recognized by Cberi China and the China Brand Economic Index Network as one of the “Most Promising Investment Firms of 2023.”

To fully leverage the guiding role of state-owned capital in investment promotion, Hefei Industrial Investment Holding Group Co., Ltd. jointly established the Hefei Industrial Investment Promotion Fund with a total size of RMB 5 billion with the counties (county-level cities) and districts under the jurisdiction of Hefei City. Among them, the Phase II Investment Promotion Fund has a total size of RMB 1.5 billion. The fund primarily focuses on key industries for development in various counties (county-level cities) and districts, such as biopharmaceuticals, high-end manufacturing, integrated circuits, and electronic information. By leveraging the fund for coordinated investment attraction and promoting city-county linkage, and through market-oriented operations and professional management, the fund aims to realize the supportive and promotional effects of capital on industrial development, thereby accelerating the high-quality development of Hefei’s strategic industries.

Tianjin Shenxin Jincheng was established with capital contributions from the Beidaihe High-Tech Industry Fund (a fund of funds established by the Qinhuangdao Beidaihe New Area) and Zhongli (Tianjin) Industry-City Integration Development Fund Management Co., Ltd. As a National Demonstration Zone for Innovation in the Life and Health Industry, the Beidaihe New Area bears the historic responsibility of pioneering reforms and innovations in the life and health sector, thereby comprehensively constructing an innovative development framework for the industry. The fund adheres to market-oriented operations and professional management, leveraging the multiplier effect of fiscal funds to accelerate the high-quality development of the New Area.

Ningbo Jinming Chuangjia was founded by a team of seasoned medical industry experts and investors. Focusing on investment in niche segments of the medical device sector, its vision is to deeply cultivate frontier new technologies and hard tech in innovative medical devices. It aims to empower visionary and pioneering entrepreneurs in the life and health sector to continuously advance, developing innovative medical devices and products capable of precise diagnosis and minimally invasive or non-invasive treatment of human diseases, thereby promoting industrial upgrading in the medical device field and safeguarding human life and health.